Home » Gilead Nears Completion of Pharmasset Deal
Gilead Nears Completion of Pharmasset Deal
Gilead Sciences has acquired about 95 percent of the outstanding shares in Pharmasset as it draws closer to closing its $11 billion deal for the drug developer.
Boston Globe
Boston Globe
Upcoming Events
-
25Apr
-
07May
-
14May
-
30May